基质金属蛋白酶2 mRNA表达量与乳腺癌转移的关系及临床意义  

Clinical significance and relationship of expression of matrix metalloproteinase-2 mRNA with breast cancer metastasis

作　　者：肖春花[1] 冯玉梅[1] 李晓青[1] 郝希山[1] 

机构地区：[1]天津医科大学附属肿瘤医院乳腺外科,300060

出　　处：《中华外科杂志》2005年第9期599-602,共4页Chinese Journal of Surgery

基　　金：天津市科技发展计划项目(013182311)

摘　　要：目的探讨乳腺癌基质金属蛋白酶2(MMP2)mRNA表达量与乳腺癌转移的关系及临床意义。方法采用荧光定量逆转录聚合酶链反应(RT PCR)方法,检测30例乳腺原发癌和配对淋巴结转移癌以及116例乳腺原发癌的MMP2mRNA表达量,比较30例乳腺原发癌和配对淋巴结转移与116例乳腺原发癌的MMP2mRNA表达量,分析MMP2mRNA表达量与乳腺癌临床病理因素的关系。结果30例乳腺淋巴结转移癌MMP2mRNA表达量低于原发癌(t=-3.293,P<0.05)。肿瘤>2cm的MMP2mRNA表达量低于肿瘤≤2cm(t=1.936,P<0.05),临床Ⅱ期和Ⅲ期的MMP2mRNA表达量低于Ⅰ期(t=2.466,P<0.05),淋巴结4个以上阳性组MMP2mRNA表达量低于1～3个阳性组(t=3.202,P<0.05)。MMP2mRNA表达量与病理类型、组织学分级、雌、孕激素受体及Her2表达无关。结论MMP2mRNA表达量在临床早期及淋巴结转移早期上调,随着肿瘤的进展表达量下调。MMP2mRNA转录水平的表达与乳腺癌转移有关。Objective To discuss the clinical significance of matrix metalloproteinase-2 (MMP-2) mRNA and the relationship of MMP-2 mRNA expression with breast cancer metastasis. Method Detect MMP-2 mRNA expression of 30 breast cancer, metastatic lymphnode and 116 clinical breast cancer samples by flurence-quantitative RT-PCR and analysis the relativity of MMP-2 mRNA expression with clinical,pathology factors. Results MMP-2 mRNA expression in 30 metastatic lymphnode is lower than in primary breast cancer(t=-3.293,P<0.05). The mRNA expression of MMP-2 in tumor﹥2 cm is lower than in tumor≤2 cm(t=1.936,P<0.05). The MMP-2 mRNA expression in stage Ⅱ、Ⅲ is lower than in stage I(t=2.466,P<0.05). The mRNA expression of MMP-2 in more than 4 lymphnodes popsitive is lower than in lymphnode 1-3 positive(t=3.202,P<0.05). The MMP-2 mRNA expression is irrelated with tissue grade、pothologic type、ER、PR and Her-2. Conclusions MMP-2 mRNA expression is up-regulated in early clinic stage、lymphnode metastatic early stage, and down regulated with tumor progressing. MMP-2 mRNA expression is related with the metastasis of breast cancer.

关 键 词：MRNA表达量 乳腺癌转移 基质金属蛋白酶2 临床意义 荧光定量逆转录聚合酶链反应 MMP-2 乳腺原发癌 淋巴结转移癌 临床病理因素 组织学分级 Her-2 孕激素受体 临床Ⅱ期 病理类型 转录水平 肿瘤 配对 阳性 早期 

分 类 号：R737.9[医药卫生—肿瘤]